About Fortress Biotech (NASDAQ:FBIO)
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500
Debt
Debt-to-Equity Ratio0.44%
Current Ratio2.72%
Quick Ratio2.71%
Price-To-Earnings
Trailing P/E Ratio-2.71
Forward P/E Ratio-2.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$187.58 million
Price / Sales1.18
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book1.81
Profitability
EPS (Most Recent Fiscal Year)($1.61)
Net Income$-66,870,000.00
Net Margins-46.69%
Return on Equity-51.57%
Return on Assets-28.08%
Miscellaneous
Employees68
Outstanding Shares51,340,000
Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
How were Fortress Biotech's earnings last quarter?
Fortress Biotech (NASDAQ:FBIO) issued its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.24. The biopharmaceutical company earned $46.89 million during the quarter, compared to analysts' expectations of $50.75 million. Fortress Biotech had a negative return on equity of 51.57% and a negative net margin of 46.69%. The firm's revenue for the quarter was up 4709.2% compared to the same quarter last year. View Fortress Biotech's Earnings History.
When is Fortress Biotech's next earnings date?
What price target have analysts set for FBIO?
4 Wall Street analysts have issued 12 month price objectives for Fortress Biotech's stock. Their predictions range from $10.00 to $11.00. On average, they anticipate Fortress Biotech's share price to reach $10.75 in the next twelve months. View Analyst Ratings for Fortress Biotech.
What are Wall Street analysts saying about Fortress Biotech stock?
Here are some recent quotes from research analysts about Fortress Biotech stock:
- 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (2/19/2018)
- 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include ProMetic Life Sciences (PFSCF), Depomed (DEPO), Synergy Pharmaceuticals (SGYP), Syros Pharmaceuticals (SYRS), Paratek Pharmaceuticals (PRTK), Cytokinetics (CYTK), Cara Therapeutics (CARA), Kala Pharmaceuticals (KALA), Corium International (CORI), Albireo Pharma (ALBO), Mersana Therapeutics (MRSN), Durect (DRRX), Strongbridge Biopharma (SBBP), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Clearside Biomedical (CLSD), Dermira (DERM) and Kadmon (KDMN).
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Chairman, CEO & Pres (Age 63)
- Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 64)
- Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. & Director (Age 52)
- Ms. Robyn M. Hunter, Chief Financial Officer (Age 56)
- Mr. Timothy M. Hillman, VP of Operations
Has Fortress Biotech been receiving favorable news coverage?
News coverage about FBIO stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a coverage optimism score of 0.22 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.01 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Fortress Biotech?
Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fortress Biotech's stock price today?
One share of FBIO stock can currently be purchased for approximately $4.31.
How big of a company is Fortress Biotech?
Fortress Biotech has a market capitalization of $224.37 million and generates $187.58 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.
How can I contact Fortress Biotech?
Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Fortress Biotech (FBIO)
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fortress Biotech (NASDAQ:FBIO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Fortress Biotech in the last 12 months. Their average twelve-month price target is $10.75, suggesting that the stock has a possible upside of 149.42%. The high price target for FBIO is $11.00 and the low price target for FBIO is $10.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.75 | $10.80 | $11.00 | $11.00 |
| Price Target Upside: | 149.42% upside | 109.71% upside | 175.69% upside | 171.60% upside |
Fortress Biotech (NASDAQ:FBIO) Consensus Price Target History
Fortress Biotech (NASDAQ:FBIO) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Fortress Biotech (NASDAQ:FBIO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Fortress Biotech (NASDAQ FBIO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 11.75%
Fortress Biotech (NASDAQ FBIO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/14/2017 | George Avgerinos | SVP | Sell | 12,000 | $3.55 | $42,600.00 | 352,495 |  |
| 12/12/2017 | George Avgerinos | SVP | Sell | 25,593 | $3.59 | $91,878.87 | 409,088 | |
| 11/6/2017 | Lindsay A Md Rosenwald | CEO | Buy | 40,000 | $25.00 | $1,000,000.00 | 40,000 | |
| 9/16/2016 | George Avgerinos | SVP | Sell | 48,912 | $2.55 | $124,725.60 | 293,000 | |
| 12/1/2014 | Lucy Lu | CFO | Buy | 5,000 | $1.45 | $7,250.00 | | |
| 11/6/2014 | Lindsay A Md Rosenwald | CEO | Buy | 150,000 | $1.61 | $241,500.00 | | |
| 11/6/2014 | Malcolm Hoenlein | Director | Buy | 25,000 | $1.61 | $40,250.00 | | |
| 11/6/2014 | Michael S Weiss | Major Shareholder | Buy | 1,000,000 | $1.61 | $1,610,000.00 | | |
| 6/2/2014 | Lucy Lu | CFO | Buy | 5,000 | $1.37 | $6,850.00 | | |
| 4/22/2014 | Kevin Horgan | Insider | Sell | 47,566 | $1.89 | $89,899.74 | | |
| 4/21/2014 | Kevin Horgan | Insider | Sell | 19,000 | $1.81 | $34,390.00 | | |
| 8/21/2013 | J Jay Lobell | Director | Buy | 5,000 | $7.37 | $36,850.00 | | |
| 7/17/2013 | Lucy Lu | CFO | Buy | 4,545 | $7.90 | $35,905.50 | | |
| 6/20/2013 | J Jay Lobell | Director | Buy | 10,000 | $7.62 | $76,200.00 | | |
| 5/31/2013 | Dale Ritter | CAO | Buy | 1,503 | $3.88 | $5,831.64 | | |
| 5/31/2013 | Lucy Lu | CFO | Buy | 4,979 | $3.88 | $19,318.52 | | |
| 5/31/2013 | Noah D Beerman | COO | Buy | 5,000 | $3.88 | $19,400.00 | | |
| 1/14/2013 | Harlan F Weisman | CEO | Buy | 20,000 | $5.71 | $114,200.00 | | |
| 11/30/2012 | Glenn L Md Cooper | Insider | Buy | 3,811 | $4.02 | $15,320.22 | | |
(Data available from 1/1/2013 forward)
Fortress Biotech (NASDAQ FBIO) News Headlines
| Source: |
|
Fortress Biotech (NASDAQ:FBIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fortress Biotech (NASDAQ:FBIO) Income Statement, Balance Sheet and Cash Flow Statement
Fortress Biotech (NASDAQ FBIO) Stock Chart for Thursday, April, 19, 2018
Loading chart…
